☰

Nicholas J. Veomett, Ph.D. - Publications

Affiliations: 
2014 Weill Cornell Medical College, New York, NY, United States 
Area:
Pharmacology, Oncology, Immunology
Tree Info Similar researchers PubMed Report error

10 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature Biotechnology. PMID 26389576 DOI: 10.1038/Nbt.3349  0.661
2014 Veomett N, Dao T, Liu H, Xiang J, Pankov D, Dubrovsky L, Whitten JA, Park SM, Korontsvit T, Zakhaleva V, Casey E, Curcio M, Kharas MG, O'Reilly RJ, Liu C, et al. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4036-46. PMID 24850840 DOI: 10.1158/1078-0432.CCR-13-2756  0.643
2013 Veomett N, Dao T, Scheinberg DA. Therapeutic antibodies to intracellular targets in cancer therapy. Expert Opinion On Biological Therapy. 13: 1485-8. PMID 23991764 DOI: 10.1517/14712598.2013.833602  0.611
2013 Mallikaratchy P, Gardner J, Nordstrøm LU, Veomett NJ, McDevitt MR, Heaney ML, Scheinberg DA. A self-assembling short oligonucleotide duplex suitable for pretargeting. Nucleic Acid Therapeutics. 23: 289-99. PMID 23848521 DOI: 10.1089/Nat.2013.0425  0.504
2013 Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science Translational Medicine. 5: 176ra33. PMID 23486779 DOI: 10.1126/Scitranslmed.3005661  0.683
2013 Dubrovsky L, Brea EJ, Veomett NJ, Dao T, Yan S, Liu C, Scheinberg DA. Therapeutic superiority of a TCR-like antibody to an intracellular WT1 oncogene peptide compared with the tyrosine kinase inhibitor imatinib in a mouse model of Philadelphia chromosome positive (Ph+) ALL. Journal of Clinical Oncology. 31: 3047-3047. DOI: 10.1200/Jco.2013.31.15_Suppl.3047  0.645
2013 Dubrovsky L, Brea E, Pankov D, Veomett N, Dao T, Yan S, Liu C, Scheinberg DA. Therapeutic Efficacy and Cure Of Sensitive and T315I Pan-Resistant Human Ph+ Leukemia In Mice Using a TCR-Like Antibody To WT1/HLA-A0201 Alone, Or In Combination With Tyrosine Kinase Inhibitors Blood. 122: 855-855. DOI: 10.1182/Blood.V122.21.855.855  0.609
2013 Pankov D, Dao T, Wang Y, Scott A, Korontsvit T, Zakhaleva V, Veomett N, Curcio M, Doubrovina E, O'Reilly RJ, Liu C, Scheinberg DA. A Bi-Specific T Cell Engaging Monoclonal Antibody (mAb) Derived From a TCR-Like Mab Specific For WT1/HLA-A0201 (ESK-BiTE) Shows a Potent Activity Against Human AML and Ph+ ALL In Mouse Models Blood. 122: 2521-2521. DOI: 10.1182/Blood.V122.21.2521.2521  0.652
2012 Tseng HM, Shum D, Bhinder B, Escobar S, Veomett NJ, Tomkinson AE, Gin DY, Djaballah H, Scheinberg DA. A high-throughput scintillation proximity-based assay for human DNA ligase IV. Assay and Drug Development Technologies. 10: 235-49. PMID 22192310 DOI: 10.1089/Adt.2011.0404  0.456
2012 Veomett N, Dao T, Pankov D, Yan S, O'Reilly RJ, Liu C, Scheinberg DA. Native and Fc Enhanced Therapeutic Human Monoclonal Antibodies Targeting the Intracellular WT1 Oncogene Product in Leukemia. Blood. 120: 2599-2599. DOI: 10.1182/Blood.V120.21.2599.2599  0.674
Show low-probability matches.